The Triple Drug Trial
PRF funds a triple combination drug trial with lonafarnib + pravastatin + zoledronate. Although the trial finds no significant improvement over lonafarnib alone, the results inform future research directions.
PRF funds a triple combination drug trial with lonafarnib + pravastatin + zoledronate. Although the trial finds no significant improvement over lonafarnib alone, the results inform future research directions.
